Page 11234..1020..»

Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

Posted: October 30, 2024 at 2:42 am

- Results show CT1812 dramatically slowed cognitive decline in patients with lower levels of plasma p-tau217, an important biomarker of Alzheimer’s disease pathology -

Read more:
Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

Posted in Global News Feed | Comments Off on Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile

Posted: October 30, 2024 at 2:42 am

Ad hoc announcement pursuant to Art. 53 LR

See the article here:
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile

Posted in Global News Feed | Comments Off on Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile

Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company

Posted: October 30, 2024 at 2:42 am

WARREN, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announced today that on October 28, 2024, it received written notice from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price requirement (the “Minimum Bid Price Requirement”), as set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Global Market.

Go here to read the rest:
Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company

Posted in Global News Feed | Comments Off on Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company

Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update

Posted: October 30, 2024 at 2:42 am

Phase 2a proof-of-concept study of SPR720 for the treatment of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) did not meet its primary endpoint, based on planned interim analysis of 16 patients

Read the original here:
Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update

Posted in Global News Feed | Comments Off on Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update

Shuttle Pharma Pays Off Senior Secured Convertible Note

Posted: October 30, 2024 at 2:42 am

GAITHERSBURG, Md., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that, during the third quarter of this year, it paid off the entirety of the outstanding balance due under its Senior Secured Convertible Note (“Note”) issued on January 11, 2023.

Continue reading here:
Shuttle Pharma Pays Off Senior Secured Convertible Note

Posted in Global News Feed | Comments Off on Shuttle Pharma Pays Off Senior Secured Convertible Note

BioVie Inc. Announces Closing of Registered Direct Offering

Posted: October 30, 2024 at 2:42 am

CARSON CITY, Nev., Oct. 29, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the closing of its previously announced registered direct offering of 1,146,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $2.83 per share.

See the article here:
BioVie Inc. Announces Closing of Registered Direct Offering

Posted in Global News Feed | Comments Off on BioVie Inc. Announces Closing of Registered Direct Offering

Cytek Biosciences to Report Third Quarter 2024 Financial Results on November 5, 2024

Posted: October 30, 2024 at 2:42 am

FREMONT, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced it will report financial results for the third quarter 2024 after market close on Tuesday, November 5, 2024. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.

Continued here:
Cytek Biosciences to Report Third Quarter 2024 Financial Results on November 5, 2024

Posted in Global News Feed | Comments Off on Cytek Biosciences to Report Third Quarter 2024 Financial Results on November 5, 2024

ADMA Biologics to Report Third Quarter 2024 Financial Results on November 7, 2024

Posted: October 30, 2024 at 2:42 am

Conference Call Scheduled for November 7, 2024, at 4:30 p.m. ET Conference Call Scheduled for November 7, 2024, at 4:30 p.m. ET

Read more:
ADMA Biologics to Report Third Quarter 2024 Financial Results on November 7, 2024

Posted in Global News Feed | Comments Off on ADMA Biologics to Report Third Quarter 2024 Financial Results on November 7, 2024

Cronos Group Inc. to Hold 2024 Third Quarter Earnings Conference Call on November 12, 2024

Posted: October 30, 2024 at 2:42 am

TORONTO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2024 third quarter earnings conference call on Tuesday, November 12, 2024 at 8:30 a.m. ET. Cronos’ senior management team will discuss the Company’s financial results and will be available for questions from the investment community after prepared remarks.

Follow this link:
Cronos Group Inc. to Hold 2024 Third Quarter Earnings Conference Call on November 12, 2024

Posted in Global News Feed | Comments Off on Cronos Group Inc. to Hold 2024 Third Quarter Earnings Conference Call on November 12, 2024

Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast

Posted: October 30, 2024 at 2:42 am

GARDEN CITY, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients, today announced that it plans to report the financial results for the second quarter of its fiscal year 2025 ended September 30, 2024 on Monday, November 11, 2024 after the market closes.

Excerpt from:
Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast

Posted in Global News Feed | Comments Off on Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast

Page 11234..1020..»